# Structured Summary: The chemokines CXCL8 and CXCL12

**ESSENTIAL PAPER INFORMATION**

*   **Original Title:** The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention
*   **Original Abstract:** Chemokines are an indispensable component of our immune system through the regulation of directional migration and activation of leukocytes. CXCL8 is the most potent human neutrophil-attracting chemokine and plays crucial roles in the response to infection and tissue injury. CXCL8 activity inherently depends on interaction with the human CXC chemokine receptors CXCR1 and CXCR2, the atypical chemokine receptor ACKR1, and glycosaminoglycans. Furthermore, (hetero)dimerization and tight regulation of transcription and translation, as well as post-translational modifications further fine-tune the spatial and temporal activity of CXCL8 in the context of inflammatory diseases and cancer. The CXCL8 interaction with receptors and glycosaminoglycans is therefore a promising target for therapy, as illustrated by multiple ongoing clinical trials. CXCL8-mediated neutrophil mobilization to blood is directly opposed by CXCL12, which retains leukocytes in bone marrow. CXCL12 is primarily a homeostatic chemokine that induces migration and activation of hematopoietic progenitor cells, endothelial cells, and several leukocytes through interaction with CXCR4, ACKR1, and ACKR3. Thereby, it is an essential player in the regulation of embryogenesis, hematopoiesis, and angiogenesis. However, CXCL12 can also exert inflammatory functions, as illustrated by its pivotal role in a growing list of pathologies and its synergy with CXCL8 and other chemokines to induce leukocyte chemotaxis. Here, we review the plethora of information on the CXCL8 structure, interaction with receptors and glycosaminoglycans, different levels of activity regulation, role in homeostasis and disease, and therapeutic prospects. Finally, we discuss recent research on CXCL12 biochemistry and biology and its role in pathology and pharmacology.
*   **DOI/Reference:** https://doi.org/10.1038/s41423-023-00974-6
*   **Authors:** Seppe Cambier, Mieke Gouwy and Paul Proost

---

### 1. OVERVIEW
This review synthesizes current knowledge on the chemokines CXCL8 and CXCL12, focusing on their molecular properties, regulation, and roles in health and disease. The central aim is to detail their interactions with receptors and glycosaminoglycans, their opposing roles in leukocyte retention versus mobilization, and their therapeutic potential. The paper is relevant for understanding inflammation and cancer, as both CXCL8 and CXCL12 are pivotal in these processes and are promising targets for pharmacological intervention.

### 2. MAIN METHODOLOGY
As a review article, the methodology involves a comprehensive synthesis of the existing scientific literature on the chemokines CXCL8 and CXCL12. The authors collated and analyzed data from structural biology, biochemistry, cell biology, and clinical studies. Information was drawn from *in vitro* experiments, *in vivo* animal models, and numerous clinical trials targeting these chemokine pathways (summarized in Tables 2, 3, and 4). The review systematically discusses their structure, interaction with G protein-coupled receptors (GPCRs) and atypical chemokine receptors (ACKRs), post-translational modifications, and roles in various pathologies, providing an integrated perspective on their interplay.

### 3. KEY FINDINGS

*   **CXCL8 (IL-8) is a potent inflammatory chemokine for neutrophils whose activity is tightly regulated.** Its function is dependent on binding to glycosaminoglycans (GAGs) to create chemotactic gradients and signaling through receptors CXCR1 and CXCR2. Post-translational proteolytic cleavage of its N-terminus dramatically increases its biological activity by up to 30-fold, creating a positive feedback loop in inflammation (Figure 5).
*   **CXCL12 (SDF-1) is a primary homeostatic chemokine that controls cell trafficking and retention, particularly in the bone marrow, via its receptor CXCR4.** In contrast to CXCL8, it also has inflammatory functions and can synergize with CXCL8 to enhance leukocyte recruitment. Unlike CXCL8, its biological activity is generally abrogated by proteolytic processing.
*   **CXCL8 and CXCL12 have a complex relationship involving both antagonism and synergy.** They play opposing roles in neutrophil homeostasis, with CXCL12 retaining neutrophils in the bone marrow and CXCL8 mobilizing them into circulation. However, in inflamed tissues, they can act synergistically to amplify the recruitment of immune cells.
*   **Targeting the CXCL8 and CXCL12 pathways is a promising but challenging therapeutic strategy.** The CXCL8-CXCR1/2 axis is a key target for anti-inflammatory and anti-cancer drugs, with many antagonists in clinical development (Table 3). Similarly, the CXCL12-CXCR4 axis is targeted for cancer therapy and stem cell mobilization. However, clinical success has been limited, partly due to the complexity of the system and species-specific differences between preclinical models and humans.

### 4. MAIN CONCLUSIONS
CXCL8 and CXCL12 are crucial chemokines with complex, context-dependent roles in inflammation and homeostasis. Their activity is fine-tuned at multiple levels, from gene expression to post-translational modification and receptor interactions. Targeting these pathways remains a promising therapeutic strategy for cancer and inflammatory diseases. However, successful drug development requires a deeper understanding of their spatiotemporal control, isoform-specific activities, and the biological differences between preclinical models and humans to overcome the limitations that have hampered past clinical trials.

### 5. STUDY HIGHLIGHTS

*   **Key Concepts:**
    *   **Inflammatory vs. Homeostatic Chemokines:** CXCL8 is a classic inflammatory chemokine induced by injury or infection, while CXCL12 is primarily a homeostatic chemokine that is constitutively expressed to manage basal cell migration. The paper emphasizes how this functional distinction can be blurred.
    *   **Post-Translational Modification as an Activity Switch:** This refers to the enzymatic alteration of a protein after its synthesis. In this context, proteolytic cleavage *activates* CXCL8, creating a positive feedback loop for inflammation, whereas the same process *inactivates* CXCL12, highlighting a critical regulatory difference.
    *   **Chemokine Synergy and Antagonism:** The concept that chemokines do not act in isolation. CXCL8 and CXCL12 can work against each other (e.g., neutrophil mobilization vs. retention) or together (e.g., synergistic chemotaxis at an inflammatory site).

*   **Essential Technical Terms:**
    *   **Chemokine:** A small secreted protein that functions as a chemoattractant, directing the migration of immune cells to a specific location in the body.
    *   **CXCL8 (Interleukin-8):** The specific chemokine that is the most potent attractant for neutrophils, a type of white blood cell that acts as a first responder to infection and injury.
    *   **CXCL12 (SDF-1):** The specific chemokine that plays a key role in retaining hematopoietic stem cells and other leukocytes in the bone marrow.
    *   **Glycosaminoglycans (GAGs):** Long, negatively charged polysaccharides present on cell surfaces and in the extracellular matrix. They bind to chemokines, immobilizing them to form stable concentration gradients that guide migrating cells.

*   **Novel Insights or Significant Contributions:**
    *   The review provides a detailed, up-to-date synthesis of the complex regulation of both CXCL8 and CXCL12, integrating structural data, post-translational processing, and receptor interactions.
    *   It offers a comprehensive comparison of the opposing yet synergistic roles of CXCL8 and CXCL12, particularly in the critical process of neutrophil trafficking.
    *   It presents a thorough overview of the current landscape of therapeutic agents targeting these pathways, summarizing ongoing clinical trials and explaining the biological challenges that have limited their clinical success to date.
